yahoo_financeOriginal article
ALNY Stock Tanks 28% as Q2 Earnings Miss Estimates, '26 Sales View Cut
EarningsnegativeNegative
AI Analysis
Summary
Alnylam Pharmaceuticals reported Q2 earnings that missed estimates and reduced its 2026 sales guidance, causing the stock to decline 28%.
Financial Highlights
Guidance
2026 sales view cut
Outcome Details
Q2 earnings missed estimates, 2026 sales guidance cut
Importance:6/10
Sentiment:
-0.85
earnings missguidance reductionstock decline
Related Companies
Read the original article
Published by yahoo_finance on July 31, 2026 3:25 PM